Hypercalcaemia in acromegaly is not always due to men-1

Hypercalcaemia in acromegaly is not always due to men-1

Detalles Bibliográficos
Main Authors:	Zabuliene, L, Tsametis, C, Karavitaki, N, Fazal-Sanderson, V, Turner, H, Wass, J
Formato:	Journal article
Publicado:	2005

Títulos similares

Acromegaly and anaplastic astrocytoma: coincidence or pathophysiological relation?
por: Fernandez, A, et al.
Publicado: (2008)

Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide.
por: Karavitaki, N, et al.
Publicado: (2008)

The value of the oral glucose tolerance test, random serum growth hormone and mean growth hormone levels in assessing the postoperative outcome of patients with acromegaly.
por: Karavitaki, N, et al.
Publicado: (2009)

Acromegaly: Treatment with somatostatin analogs
por: Karavitaki, N, et al.
Publicado: (2005)

Pegvisomant: a new treatment modality for acromegaly.
por: Karavitaki, N, et al.
Publicado: (2004)

Enlarged hands and feet - Not always acromegaly
por: Vikrant Ghatnatti, et al.
Publicado: (2012-01-01)

Pegvisomant for acromegaly: does it always works?
por: Sebastian J. Neggers, et al.

The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
por: Karavitaki, N, et al.
Publicado: (2005)

Hypercalcaemia due to immobility, about a case
por: Diego E. Sánchez-Herrera, et al.
Publicado: (2023-10-01)

Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab.
por: Karuppiah, D, et al.
Publicado: (2014)

Acute octreotide suppression test (100 mu g sc): a valuable tool for predicting the long-term response to the long-acting somatostatin analogs in patients with active acromegaly
por: Karavitaki, N, et al.
Publicado: (2005)

Infantile hypercalcaemia type 1: a vitamin D-mediated, under-recognised cause of hypercalcaemia
por: Ryizan Nizar, et al.
Publicado: (2021-09-01)

Radiation-induced hypopituitarism.
por: Fernandez, A, et al.
Publicado: (2009)

New treatments for acromegaly.
por: Wass, J, et al.
Publicado: (1998)

A comparison of lanreotide and octreotide LAR for treatment of acromegaly.
por: Turner, H, et al.
Publicado: (1999)

Recent advances in the management of acromegaly [version 1; referees: 2 approved]
por: Georgia Ntali, et al.
Publicado: (2015-12-01)

AIP Mediates the Effects of Somatostatin Analogues in Acromegaly - Evidence from Clinical and Experimental Studies.
por: Chahal, H, et al.
Publicado: (2010)

Plasmapheresis-Induced Hypercalcaemia
por: Anas-Alwogud Abdelmogheth, et al.
Publicado: (2013-02-01)

Reduction of elevated IGF-1 levels in coincident amyotrophic lateral sclerosis and acromegaly.
por: Pereira, E, et al.
Publicado: (2010)

Evidence for the effectiveness of radiotherapy in the treatment of acromegaly.
por: Wass, J
Publicado: (1997)

Long-term effects of radiotherapy for acromegaly.
por: Wass, J
Publicado: (1996)

Radiotherapy in acromegaly: a protagonists viewpoint.
por: Wass, J
Publicado: (2003)

Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
por: Turner, H, et al.
Publicado: (2004)

Symptomatic hypercalcaemia in paediatric tuberculosis
por: H.A. Payne, et al.
Publicado: (2011-03-01)

Hypercalcaemia due to Sarcoidosis during Treatment with Avelumab for Metastatic Merkel Cell Carcinoma
por: Sandy Tun Min, et al.
Publicado: (2019-08-01)

Paraneoplastic Hypercalcaemia Associated with TCC of Bladder
por: A. B. Patel, et al.
Publicado: (2004-01-01)

Investigation protocol: acromegaly and its investigation.
por: Duncan, E, et al.
Publicado: (1999)

Hypercalcaemia Mimicking STEMI on Electrocardiography
por: Joseph Donovan, et al.
Publicado: (2010-01-01)

Vitamin D toxicity and hypercalcaemia
por: Pooja Singh, et al.
Publicado: (2021-01-01)

Dynamic testing in the diagnosis and follow-up of patients with acromegaly.
por: Wass, J
Publicado: (2003)

Somatostatin Analogue Treatment Increases AIP Protein Expression in Somatotroph Tumours from Patients with Acromegaly and in GH3 Cells in vitro.
por: Chahal, H, et al.
Publicado: (2011)

DEPOT BROMOCRIPTINE IN THE TREATMENT OF PROLACTINOMAS AND ACROMEGALY
por: Grossman, A, et al.
Publicado: (1985)

Depot-bromocriptine treatment for prolactinomas and acromegaly.
por: Grossman, A, et al.
Publicado: (1986)

Two underlying diseases causing hypercalcaemia?
por: Pazianas, M, et al.
Publicado: (2002)

A Case of Diabetes Mellitus and Hypercalcaemia
por: Anirban Majumder, et al.
Publicado: (2015-07-01)

Review: Endocrine and metabolic emergencies: hypercalcaemia
por: Richard Carroll, et al.
Publicado: (2010-12-01)

Two Different Causes of Paediatric Hypercalcaemia
por: Stepan Kutilek, et al.
Publicado: (2018-12-01)

Schimidt Syndrome: An Unusual Cause of Hypercalcaemia
por: Nisha Jose, et al.
Publicado: (2016-05-01)

Differing effects on gall-bladder motility of lanreotide SR and octreotide LAR for treatment of acromegaly.
por: Turner, H, et al.
Publicado: (1999)

Clinical MEN-1 among a large cohort of patients with acromegaly
por: Nachtigall, LB, et al.
Publicado: (2020)